Investing.com - Merck&Co reported on Thursday second quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Merck&Co announced earnings per share of $1.31 on revenue of $11.40B. Analysts polled by Investing.com anticipated EPS of $1.4 on revenue of $11.09B.
Merck&Co shares are down 0% from the beginning of the year, still down 6.44% from its 52 week high of $83.72 set on September 3, 2020. They are under-performing the S&P Global 100 which is up 15.77% from the start of the year.
Merck&Co follows other major Healthcare sector earnings this month
Merck&Co's report follows an earnings beat by J&J on July 21, who reported EPS of $2.48 on revenue of $23.31B, compared to forecasts EPS of $2.29 on revenue of $22.49B.
UnitedHealth had beat expectations on July 15 with second quarter EPS of $4.7 on revenue of $71.32B, compared to forecast for EPS of $4.43 on revenue of $69.51B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar